Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C—C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodies
Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-α4β7 integrin antibody.
1. A method of treating or reducing the development of inflammatory bowel disease in a mammal, said method comprising administering a suitable amount of a CCR9 chemokine receptor inhibitor with an anti-TNFα antibody, wherein the CCR9 chemokine receptor inhibitor is
or a salt thereof.
2. The method of claim 1 , wherein the inflammatory bowel disease is Crohn's disease (CD) or ulcerative colitis (UC).
3. The method of claim 1 , wherein the CCR9 chemokine receptor inhibitor and the anti-TNFα antibody are administered in a combination formulation.
4. The method of claim 1 , wherein the CCR9 chemokine receptor inhibitor is administered prior to administration of the anti-TNFα antibody blocking antibody.
5. The method of claim 1 , wherein the inflammatory bowel disease is Crohn's disease (CD).
6. The method of claim 1 , wherein the inflammatory bowel disease is ulcerative colitis (UC).
7. The method of claim 1 , wherein the CCR9 chemokine receptor inhibitor and the anti-TNFα antibody are administered sequentially.
8. The method of claim 1 , wherein the CCR9 chemokine receptor inhibitor is administered after administration of the anti-TNFα antibody blocking antibody.